Call for 2020 Chinese Pharmacopoeia to radically raise standards

Bi Jingquan, current director of the China Food and Drug Administration, has issued a rallying cry at an event marking the founding of the 11th Chinese Pharmacopoeia Commission.

The Chinese Pharmacopoeia, first issued more than half-a-century ago, is recompiled every five years to set the standard for drug regulation in China, and work on the 2020 edition is now formally beginning.

Explaining its importance, Mr Bi said: “The pharmacopoeia is the quintessence of the scientific and technological development achievements of drugs, the symbol for the development level of the drug industry of a country, the basic standard for the pharmaceutical manufacturers and distributors and the criterion for the drug administration work.”